Treatment Options for Pneumonia
Guidelines for the treatment of diseases are published by the related societies in the respective nations. These are based on prior evidence of clinical benefit from specific therapies. The evidence is graded to provide a clear understanding.
- Level I — High level of evidence. Evidence from well-conducted, randomized controlled trials.
- Level II — Moderate level of evidence. Evidence from well-designed, controlled trials without randomization. (Randomization is a process where research participants are assigned to either the investigational group or the control group randomly (by chance not by choice). The goal of randomization is to produce comparable groups in terms of general participant characteristics, such as age or gender, and other key factors that affect the probable course the disease would take. A randomized, controlled trial is considered the most reliable and impartial method of determining what medical interventions work the best).
- Level III – Low level of evidence. Evidence from case studies and expert opinion. In some instances, therapy recommendations come from antibiotic susceptibility data without clinical observations.
1. Previously healthy and no use of antimicrobials within the previous 3 months
- A macrolide (strong recommendation; level I evidence)
- Doxycyline (weak recommendation; level III evidence)
- A respiratory fluoroquinolone (moxifloxacin, gemifloxacin, or levofloxacin [750 mg]) (strong recommendation; level I evidence)
- A β-lactam plus a macrolide (strong recommendation; level I evidence)
Inpatients and Non-ICU Treatment
A respiratory fluoroquinolone (strong recommendation; level I evidence)
A β-lactam plus a macrolide (strong recommendation; level I evidence)
Inpatients, ICU treatment
If community acquired-methicillin resistant Staphylococcus aureus (CA-MRSA) is a consideration, add vancomycin or linezolid (moderate recommendation; level III evidence).
Next page: Routes of Transmission of Pnemonia
Written by: Healthplus24 team
Date last updated: July 31, 2012